Biogen (BIIB) YTD return
Updated November 02, 2026 · Data: Yahoo Finance
Price chart
BIIB vs its sector
Outperforming its sector. BIIB is 11.76 points ahead of the Health Care sector average, which covers 60 ranked S&P 500 stocks.
Biogen (BIIB) is up +41.49% year-to-date in 2026, ranking #66 of 500 ranked S&P 500 stocks. It closed 2025 at $175.99 and trades at $249.01 as of November 02, 2026. $1,000 invested on December 31, 2025 would be worth $1,414.90 today. That puts it 11.76 points ahead of the Health Care sector average of +29.73%.
Recent performance
Biogen (BIIB) has gained 13.25% over the past month, outpacing the S&P 500 by 15.60%, and gained 19.46% over the past three months (ahead of the index by 21.98%). It is trading 1.90% below its 52-week high of $253.84, set on 2026-10-22.
Latest BIIB news
- Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...GuruFocus.com · 2026-10-31
- What Just Happened To Alnylam Stock?Trefis · 2026-10-30
- Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC SaysMT Newswires · 2026-10-29
- Bernstein Adjusts Price Target on Biogen to $278 From $236MT Newswires · 2026-10-29
- UBS Adjusts Price Target on Biogen to $300 From $270, Keeps Buy RatingMT Newswires · 2026-10-29
Headlines via Yahoo Finance, updated daily.
Where to invest in BIIB
Popular stock brokerages:
We may earn a commission if you sign up through these links, at no extra cost to you.
BIIB YTD return FAQ
What is Biogen (BIIB)'s YTD return in 2026?
Biogen (BIIB) is up +41.49% year-to-date in 2026, as of November 02, 2026.
What was Biogen (BIIB)'s price at the start of 2026?
Biogen (BIIB) closed at $175.99 on December 31, 2025 and trades at $249.01 as of November 02, 2026.
Where does Biogen (BIIB) rank by YTD return in 2026?
Biogen (BIIB) ranks #66 of 500 S&P 500 stocks by YTD return in 2026, as of November 02, 2026.
For informational purposes only, not financial advice.
About · Contact · Privacy Policy · Affiliate Disclosure · Methodology
© 2026 MZX MEDIA LLC. All rights reserved.